systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075-082X_14.3.79-83systhiper-521Research ArticleСТАТЬИARTICLESВзаимодействие антигипертензивных лекарственных средств и розувастатина: фокус на безопасность, эффективность и перспективыInteraction of antihypertensive drugs and rosuvastatin: focus on safety, efficiency and prospectsЛучининаЕ. В.LuchininaE. V.noemail@neicon.ruКомпаниецО. Г.KompanietsO. G.Olga-Kompaniets1@yandex.ruКижватоваН. В.KizhvatovaN. V.noemail@neicon.ruФГБОУ ВО «СГМУ им. В.И.Разумовского»РоссияV.I.Razumovsky Saratov State Medical University of the Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО КубГМУРоссияKuban State Medical University of the Ministry of Health of the Russian FederationRussian Federation2017231220221437983Copyright © Лучинина Е.В., Компаниец О.Г., Кижватова Н.В., 20222022Лучинина Е.В., Компаниец О.Г., Кижватова Н.В.Luchinina E.V., Kompaniets O.G., Kizhvatova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/521

Артериальная гипертензия и дислипидемия являются часто встречающейся коморбидной патологией, регистрирующейся у 40-70% пациентов. Статины показаны как для первичной, так и для вторичной профилактики сердечно-сосудистых заболеваний и осложнений. Мы попытались проанализировать некоторые данные о статинах и их взаимодействии с антигипертензивными препаратами. Розувастатин является препаратом, обеспечивающим интенсивное снижение липопротеидов низкой плотности, не требует коррекции дозы при применении совместно с антигипертензивными препаратами. Отсутствие ингибиции и активации розувастатином цитохромов Р450 обеспечивает низкий риск негативных взаимодействий в клинических ситуациях вынужденной полипрагмазии. Практикующим врачам необходимо учитывать вероятность побочных реакций при сочетании статинов с рядом препаратов из других клинико-фармакологических групп.

Arterial hypertension and dyslipidemia is a very frequent comorbid condition. Arterial hypertension and dyslipidemia are combined in 40-70% of patients. The statins is the basic drug in primary and secondary prevention of cardiovascular disease and in the reduction of cardiovascular complications. We`ve attempted to summarize some data about the statins and interaction of antihypertensive drugs. Rosuvastatin is a medicine that provides an intensive reduction of low-density lipoproteins, does not require dose adjustment when applied in conjunction with antihypertensive drugs. The absence of inhibition and activation of rosuvastatin cytochrome P450 provides a low risk of negative interactions in the clinical situations of induced polypharmacy. Every clinician is to remember that it`s crucial to take into account some adverse reactions combining the statins with drugs of other pharmacological groups.

артериальная гипертензиядислипидемиирозувастатинантигипертензивные препаратыаrterial hypertensiondyslipidemiarosuvastatinantihypertensive drugsReferencesMancia G, Fagard R, Narkiewicz K. et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2013 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. Eur Heart J. DOI: 10.1093/eurheartj/eht151Mancia G, Fagard R, Narkiewicz K. et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2013 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. Eur Heart J. DOI: 10.1093/eurheartj/eht151Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиол. вестн. 2015; 1: 5-30.Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиол. вестн. 2015; 1: 5-30.Catapano A. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999-3058.Catapano A. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999-3058.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. М., 2017. http://www.scardio.ru/ content/Guidelines/rek_lipid_2012.pdfДиагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. М., 2017. http://www.scardio.ru/ content/Guidelines/rek_lipid_2012.pdfPiepoli M. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37 (29): 2315-81.Piepoli M. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37 (29): 2315-81.Waters D.D, Guyton J.R, Herrington D.M. et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93 (2): 154-8.Waters D.D, Guyton J.R, Herrington D.M. et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93 (2): 154-8.Karlson B.W, Palmer M.K, Nicholls S. et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines. A VOYAGER meta-analysis. Atherosclerosis. 2015; 241 (2): 450-4.Karlson B.W, Palmer M.K, Nicholls S. et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines. A VOYAGER meta-analysis. Atherosclerosis. 2015; 241 (2): 450-4.LaRosa J.C, Grundy S.M, Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425-35.LaRosa J.C, Grundy S.M, Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425-35.Jones P.H, Davidson M.H, Stein E.A. et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.Jones P.H, Davidson M.H, Stein E.A. et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.Leiter L.A, Rosenson R.S, Stein E. et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154-e164.Leiter L.A, Rosenson R.S, Stein E. et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154-e164.Nissen S.E, Nicholls S.J, Sipahi I. et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.Nissen S.E, Nicholls S.J, Sipahi I. et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.Государственный реестр лекарственных средств. http://grls.rosminzdrav.ruГосударственный реестр лекарственных средств. http://grls.rosminzdrav.ruChristie M, Ballantynea RC, Hoogeveena JL et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg pluse zetimibe 10 mg vs. simvastatin 40 or 80 mg pluse zetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86-93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022Christie M, Ballantynea RC, Hoogeveena JL et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg pluse zetimibe 10 mg vs. simvastatin 40 or 80 mg pluse zetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232: 86-93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022Смоленская О.Г., Макарова, В.Л., Зенин Д.М., Суслов С.А. Значение артериальной гипертонии и нарушений углеводного обмена в развитии коронарного атеросклероза. Системные гипертензии. 2008; 5 (1).Смоленская О.Г., Макарова, В.Л., Зенин Д.М., Суслов С.А. Значение артериальной гипертонии и нарушений углеводного обмена в развитии коронарного атеросклероза. Системные гипертензии. 2008; 5 (1).Синькова Г.М. Факторы общего сердечно-сосудистого риска у больных артериальной гипертензией в сельских и отдаленных районах Иркутской области. Сиб. мед. журн. 2009; 91 (8): 98-100.Синькова Г.М. Факторы общего сердечно-сосудистого риска у больных артериальной гипертензией в сельских и отдаленных районах Иркутской области. Сиб. мед. журн. 2009; 91 (8): 98-100.Khokhlov A.L, Javorskij A.N, Ignat'ev VS et al. Safety culture of drug therapy. Yaroslavl, 2011.Khokhlov A.L, Javorskij A.N, Ignat'ev VS et al. Safety culture of drug therapy. Yaroslavl, 2011.Schröder J, Goltz L, Knoth H. Simvastatin and Amlodipin - a clinically relevant drug-interaction? Dtsch Med Wochenschr 2016; 141 (21): 1575-7.Schröder J, Goltz L, Knoth H. Simvastatin and Amlodipin - a clinically relevant drug-interaction? Dtsch Med Wochenschr 2016; 141 (21): 1575-7.Pietsch U, Müller-Höcker C, Filipovic M. Brown urine: Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone. Anaesthesist 2016; 65 (5): 366-8. DOI: 10.1007/s00101-016-0171-6Pietsch U, Müller-Höcker C, Filipovic M. Brown urine: Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone. Anaesthesist 2016; 65 (5): 366-8. DOI: 10.1007/s00101-016-0171-6Shaik A.N, Bohnert T, Williams D.A. et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci 2016; 105 (6): 1976-86. DOI: 10.1016/j.xphs.2016.03.011Shaik A.N, Bohnert T, Williams D.A. et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. J Pharm Sci 2016; 105 (6): 1976-86. DOI: 10.1016/j.xphs.2016.03.011Leoncini M, Toso A, Maioli M, Bellandi F. Statin and clopidogrel pharmacological interaction. G Ital Cardiol (Rome) 2013; 14 (9): 574-84. DOI: 10.1714/1311.14483Leoncini M, Toso A, Maioli M, Bellandi F. Statin and clopidogrel pharmacological interaction. G Ital Cardiol (Rome) 2013; 14 (9): 574-84. DOI: 10.1714/1311.14483Panes O, González C, Hidalgo P. et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017; 257: 164-71. DOI: 10.1016/j.atherosclerosis.2016.12.019Panes O, González C, Hidalgo P. et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017; 257: 164-71. DOI: 10.1016/j.atherosclerosis.2016.12.019Zhaohuan Li, Lin Wang, Xiaobo Hu et al. Effect of rosuvastatin on atherosclerotic plaque stability. Atherosclerosis 2016; 248: 27-35. https://doi.org/10.1016/j.atherosclerosis.2016.02.028Zhaohuan Li, Lin Wang, Xiaobo Hu et al. Effect of rosuvastatin on atherosclerotic plaque stability. Atherosclerosis 2016; 248: 27-35. https://doi.org/10.1016/j.atherosclerosis.2016.02.028Andora M, Suciub M, Cristescub C. et al. Short-term rosuvastatin therapy influence on restored endothelial function in hypertensive patients. Atherosclerosis 2014; 235 (2): e92. https://doi.org/10.1016/j.atherosclerosis.2014.05.243Andora M, Suciub M, Cristescub C. et al. Short-term rosuvastatin therapy influence on restored endothelial function in hypertensive patients. Atherosclerosis 2014; 235 (2): e92. https://doi.org/10.1016/j.atherosclerosis.2014.05.243Jamol Uzokov, Anis Alyavi, Baxrom Alyavi. Volume Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome Author links open overlay panel. Atherosclerosis 2017; 263: e241. https://doi.org/ 10.1016/j.atherosclerosis.2017.06.782Jamol Uzokov, Anis Alyavi, Baxrom Alyavi. Volume Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome Author links open overlay panel. Atherosclerosis 2017; 263: e241. https://doi.org/ 10.1016/j.atherosclerosis.2017.06.782Kim S.H, Lee HL, Lim W.H. et al. Efficacy and safety of fixed-dose combination of olmesartan medoxomil and rosuvastatin in Korean patients with hypertension and dyslipidemia. Atherosclerosis 2016; 252: e57.Kim S.H, Lee HL, Lim W.H. et al. Efficacy and safety of fixed-dose combination of olmesartan medoxomil and rosuvastatin in Korean patients with hypertension and dyslipidemia. Atherosclerosis 2016; 252: e57.Chen J.1, Li D, Schaefer R, Mehta J.L. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184 (2). https://doi.org/10.1016/j.atherosclerosis.2005.04.016Chen J.1, Li D, Schaefer R, Mehta J.L. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184 (2). https://doi.org/10.1016/j.atherosclerosis.2005.04.016Jandeleit-Dahm K, Rajaram Y, Giunti S. et al. Th-P16:286 Effects of rosuvastatin combined with candesartan on oxidative stress and inflammatory parameters in diabetes accelerated atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 556. https://doi.org/10.1016/S1567-5688(06)82244-0Jandeleit-Dahm K, Rajaram Y, Giunti S. et al. Th-P16:286 Effects of rosuvastatin combined with candesartan on oxidative stress and inflammatory parameters in diabetes accelerated atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 556. https://doi.org/10.1016/S1567-5688(06)82244-0

The authors declare that there are no conflicts of interest present.